Moolec Competitors
| MLEC Stock | 5.35 0.27 5.31% |
Moolec Science vs NewcelX Correlation
Poor diversification
The correlation between Moolec Science SA and NCEL is 0.71 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Moolec Science SA and NCEL in the same portfolio, assuming nothing else is changed.
Moving together with Moolec Stock
Moving against Moolec Stock
| 0.74 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.68 | DSGN | Design Therapeutics | PairCorr |
| 0.58 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.47 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.43 | ENGN | enGene Holdings Common | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Moolec Science's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Moolec Science Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Moolec Science and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Moolec and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Moolec Science SA does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Moolec Stock performing well and Moolec Science Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Moolec Science's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| VRAX | 5.32 | (1.01) | 0.00 | (0.28) | 0.00 | 7.89 | 92.80 | |||
| ELAB | 5.40 | (3.44) | 0.00 | (1.28) | 0.00 | 5.71 | 53.38 | |||
| NKGN | 4.98 | 2.05 | 0.00 | 7.23 | 0.00 | 20.00 | 68.90 | |||
| GLMD | 4.01 | (1.02) | 0.00 | (1.47) | 0.00 | 8.04 | 21.39 | |||
| WINT | 7.14 | (2.89) | 0.00 | (0.73) | 0.00 | 16.67 | 58.33 | |||
| GTBP | 5.26 | 0.02 | 0.00 | 0.16 | 7.63 | 10.84 | 51.03 | |||
| TIVC | 5.06 | (1.31) | 0.00 | (0.59) | 0.00 | 10.43 | 46.76 | |||
| DRMA | 6.57 | (0.60) | 0.00 | (0.14) | 0.00 | 16.18 | 61.86 | |||
| XRTX | 2.80 | (0.42) | 0.00 | (0.23) | 0.00 | 7.02 | 17.42 | |||
| NCEL | 5.76 | (1.25) | 0.00 | (1.62) | 0.00 | 10.12 | 39.40 |
Cross Equities Net Income Analysis
Compare Moolec Science SA and related stocks such as Virax Biolabs Group, Elevai Labs Common, and NKGen Biotech Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRAX | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (651 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (18.5 M) | (27.6 M) | (31.9 M) | (18.6 M) | (6.9 M) | (7.5 M) | (6.8 M) | (7.1 M) |
| WINT | (2.8 M) | (21 M) | (37.3 M) | (45.2 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (30.3 M) | (67.6 M) | (39.2 M) | (20.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| TIVC | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (3.6 M) | (8.5 M) | (10.1 M) | (8.2 M) | (5.7 M) | (5.1 M) | (5.3 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.8 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| XRTX | (36.9 K) | (36.9 K) | (36.9 K) | (36.9 K) | (36.9 K) | (414.8 K) | (414.8 K) | (474.2 K) | (3.8 M) | (485.5 K) | (1 M) | (1.3 M) | (7 M) | (2.2 M) | (4.8 M) | (4.3 M) | (4.1 M) |
| NCEL | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (5.1 K) | (5.4 M) | (2.9 M) | (11.9 M) | (16.5 M) | (12.2 M) | (2 M) | (1.8 M) | (1.9 M) |
Moolec Science SA and related stocks such as Virax Biolabs Group, Elevai Labs Common, and NKGen Biotech Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Moolec Science SA financial statement analysis. It represents the amount of money remaining after all of Moolec Science SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Moolec Science Competitive Analysis
The better you understand Moolec Science competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Moolec Science's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Moolec Science's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Moolec Science Competition Performance Charts
Five steps to successful analysis of Moolec Science Competition
Moolec Science's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Moolec Science SA in relation to its competition. Moolec Science's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Moolec Science in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Moolec Science's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Moolec Science SA, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Moolec Science position
In addition to having Moolec Science in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small & Mid Caps ETFs Thematic Idea Now
Small & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Moolec Science Correlation with its peers. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could Moolec diversify its offerings? Factors like these will boost the valuation of Moolec Science. Expected growth trajectory for Moolec significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Moolec Science data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (258.69) | Revenue Per Share | Quarterly Revenue Growth 9.483 | Return On Assets | Return On Equity |
Investors evaluate Moolec Science SA using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Moolec Science's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Moolec Science's market price to deviate significantly from intrinsic value.
Understanding that Moolec Science's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moolec Science represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Moolec Science's market price signifies the transaction level at which participants voluntarily complete trades.